Abstract #2369

T1 relaxivity in the bone marrow to monitor response to therapy in acute myeloid leukemia xenografts

Ana L. Gomes¹, Diana Passaro¹, Dominique Bonnet¹, and Bernard Siow²

¹Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, London, United Kingdom, ²In Vivo Imaging, The Francis Crick Institute, London, United Kingdom

Mouse models of cancer are extensively used to better understand the pathobiology of the disease, to test potential novel therapies, and for the development of diagnostic and prognostic imaging tools. Currently, diagnosis of acute myeloid leukemia (AML) is quite invasive. It is based predominantly on blast quantification in the blood and bone marrow (BM) analysis, and imaging is not part of the clinical follow-up of the patients. T1 relaxivity of the mouse BM has not been reported previously. . BM of mice injected with AML cells from patients present higher T1 relaxation values than normal BM, and it further increased after chemotherapy treatment. Although analysis of bigger cohorts of patients would be required, our data suggest a good potential for BM T1 monitoring as a non-invasive marker for AML resistance to therapy.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.